Nikos Pekiaridis | Lightrocket | Getty Images

Moderna’s New covid vaccine prepared strong immune response The biotech company said on Thursday that it is now in early clinical trials against the dominant “Eris” variant and another fast-spreading strain of the virus.

The updated shot is designed to target the Omicron subvariant XBB.1.5, but the results suggest the jab may still be effective against new variants of the virus that are taking hold across the country. This includes Eris and another variant nicknamed “Fornax” – both of which are also descendants of the Omicron virus variant.

Moderna’s vaccine and new shots pfizer And Novavax It will be implemented in a few weeks, pending possible approval from the Food and Drug Administration.

Meanwhile the number of Covid-related hospitalizations due to Eris and other variants continues to rise, though remains below the summer peak that caused a strain on hospitals this time last year.

Aeris, also known as EG.5, was responsible for 17.3% of all cases earlier this month, according to the Centers for Disease Control and Prevention.

The World Health Organization has designated Eris a “variant of interest,” which means it will be monitored for mutations that could make it more severe.

Fornax, or FL 1.5.1, has also begun to increase in some parts of the US, the CDC said earlier this month, accounting for 8.6% of all cases nationwide.

Leave a Reply

Your email address will not be published. Required fields are marked *